Video
Use and Misuse of Topical Corticosteroids in Psoriasis.
In this Take Ten with IPC video, Professor Peter van de Kerkhof discusses the use and misuse of topical corticosteroids…
In this Take Ten with IPC video, Professor Peter van de Kerkhof discusses the use and misuse of topical corticosteroids…
Watch VideoIn this Take Ten with IPC video, Professor Peter van de Kerkhof discusses the use and misuse of systemic…
Watch VideoThe International Psoriasis Council (IPC) and the National Psoriasis Foundation (NPC) have released a joint position…
View ReportIPC Chief Medical Officer Dr. Peter van de Kerkhof discusses the rise of an aging population, the comorbidities and…
Watch VideoEarly and effective treatment in psoriasis mitigates cumulative chronic disease burden and may prevent psoriatic…
View ReportKey takeaways from the 2025 EADV Congress in Paris, including the IPC Symposium on psoriasis, Free Communication…
View ReportView Report
Conflicts of interest Dr Al-Gawahiri carried out clinical trials for Janssen. All funding is not personal but goes to…
View ReportThis article provides an evidence-based update on psoriasis in individuals with skin of color (SOC), highlighting…
View ReportGeneralized pustular psoriasis(GPP)lacks internationally accepted definitions and diagnostic criteria, impeding timely…
View ReportThe International Psoriasis Council and the National Psoriasis Foundation publish findings on psoriasis disease…
View MoreThe patient perspective has become even more important in the wake of the pandemic. Here’s how Clinica Dermacross is…
Read MoreThirty-six statements on various aspects of telemedicine according to the nominal group technique to reach a consensus…
View ReportThe objective of the present study was to further explore the extent of patient burden when psoriasis affects special…
View ReportAMERICAN ACADEMY OF DERMATOLOGY ANNUAL MEETING (AAD) | NEW ORLEANS, LA Thursday, March 16 14:00 - 17:00…
Recently, a study was conducted on the effect of apremilast on vascular inflammation and cardiometabolic functions with…
Read MoreThe IPC is a proud supporter of World Psoriasis Day by uniting for action with IFPA to advance care and change the…
Read MorePersonalized care has become increasingly utilized in the past two few decades, evolving as we have gained a greater…
Read MoreDr. van de Kerkhof reviews the current treatments for generalized pustular psoriasis, there limitations, and the need…
Watch Video| Cookie | Duration | Description |
|---|---|---|
| cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.
What were the key takeaways from the 2026 AAD Annual Meeting? IPC shares updates on diagnostic challenges, psoriasis therapies, and late-breaking research from leading experts.
A new regional collaboration led by IPC and partner organizations aims to improve diagnosis, treatment, and care coordination for psoriasis and psoriatic arthritis across Latin America.
IPC recognizes its 2025 Fellows as IPC Jr. Councilors following the completion of their fellowship. This transition recognizes their contributions to psoriasis research, education, and global collaboration, and marks their expanded role in the IPC network.
The International Psoriasis Council welcomes Mari Løset and Maxwell Sauder as new Councilors, supporting IPC’s global mission in psoriasis research and care.
In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.